Methylamine → HCID 66744496, compound
Reaction equation
[NH2:1][C:2]1[N:3]=[CH:4][C:5]([C:21]2[CH2:22][CH2:23][N:24]([C:27](=[O:30])[CH2:28][CH3:29])[CH2:25][CH:26]=2)=[N:6][C:7]=1[C:8]1[O:9][C:10]([C:13]2[CH:18]=[CH:17][C:16]([CH2:19]Br)=[CH:15][CH:14]=2)=[N:11][N:12]=1.[CH3:31][NH2:32]>C1COCC1.CN(C=O)C>[NH2:1][C:2]1[N:3]=[CH:4][C:5]([C:21]2[CH2:22][CH2:23][N:24]([C:27](=[O:30])[CH2:28][CH3:29])[CH2:25][CH:26]=2)=[N:6][C:7]=1[C:8]1[O:9][C:10]([C:13]2[CH:18]=[CH:17][C:16]([CH2:19][NH:32][CH3:31])=[CH:15][CH:14]=2)=[N:11][N:12]=1Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 2
Procedure
A solution of 1-[4-[5-amino-6-[5-[4-(bromomethyl)phenyl]-1,3,4-oxadiazol-2-yl]pyrazin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]propan-1-one (20 mg, 0.04 mmol) and a solution of methanamine (107 μL of 2 M, 0.21 mmol) in THF was heated at 65° C. for 6 h. The reaction mixture was allowed to cool to room temperature and the solvents were evaporated under reduced pressure. The crude material obtained was dissolved in DMF (1 mL), filtered and purified by mass directed reverse phase LC/MS (1-99% ACN/H2O (5 mM HCl)) to yield 1-[4-[5-amino-6-[5-[4-(methylaminomethyl)phenyl]-1,3,4-oxadiazol-2-yl]pyrazin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]propan-1-one (9 mg, 45%). 1H NMR (400 MHz, DMSO-d6) δ 9.28 (s, 2H), 8.58 (s, 1H), 8.18 (d, J=7.7 Hz, 2H), 7.80 (d, J=8.0 Hz, 2H), 7.63 (s, 2H), 6.66 (s, 1H), 4.30-4.13 (m, 4H), 3.70 (dt, J=16.2, 5.4 Hz, 2H), 2.71 (s, 1H), 2.59 (t, J=5.2 Hz, 4H), 2.41 (dt, J=21.8, 7.3 Hz, 2H), 1.03 (q, J=7.0 Hz, 3H). LC/MS m/z 420.5 [M+H]+.
Workup
- customthe solvents were evaporated under reduced pressure
- customThe crude material obtained
- filtrationfiltered
- custompurified by mass
Sources & evidence
- ORD record
- ord-a77989c72ca143de9c74eed22e5c75c0
- Source dataset
- uspto-grants-2013_04
- Patent number
- US08410112B2
Reaction notes
Loading…